Compare VLRS & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLRS | SPTX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.4M | 1.1B |
| IPO Year | 2013 | 2026 |
| Metric | VLRS | SPTX |
|---|---|---|
| Price | $6.79 | $24.06 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $9.16 | N/A |
| AVG Volume (30 Days) | ★ 437.1K | 109.1K |
| Earning Date | 04-27-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.96 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.79 | $17.59 |
| 52 Week High | $10.80 | $28.38 |
| Indicator | VLRS | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 53.65 |
| Support Level | $6.50 | $23.23 |
| Resistance Level | $8.03 | $28.38 |
| Average True Range (ATR) | 0.25 | 2.16 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 43.87 | 26.18 |
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.